PV Bulletin

FDA Final Guidance on Postapproval Requirements and Resources for ANDAs

FDA issued final guidance clarifying post-approval requirements for ANDA holders under 21 CFR 314.70 (supplements), 314.80 (post-marketing safety reporting), and 314.81 (annual reports).

Primary source: US Food and Drug Administration (FDA)

PV Impact Brief

Urgency: LowConfidence: high

What changed

FDA published final guidance on certain postapproval requirements for ANDA holders, reiterating obligations for post-approval supplements, annual reports, and post-marketing safety reporting under 21 CFR 314.80.

Why it matters

This guidance impacts all ANDA holders by clarifying FDA expectations for safety reporting and maintenance, ensuring compliance with post-marketing pharmacovigilance requirements.

Action needed

Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Country ComplianceICSRLabeling
Owner

Regulatory Intelligence Lead

Review cadence

quarterly

Policy change details

Document type
Guideline
Policy status
final
Publication date
2026-06-04
Policy change
This final guidance assists Abbreviated New Drug Application (ANDA) holders in understanding and complying with certain post-approval requirements, focusing on administrative and procedural obligations.

Key changes

The guidance clarifies procedures for post-approval supplements (21 CFR 314.70), annual reports (21 CFR 314.81), and post-marketing safety reporting obligations (21 CFR 314.80). It serves as a centralized resource for generic drug manufacturers to ensure they meet maintenance requirements after approval.

Affected workflows

Country ComplianceICSRLabeling

Responsible groups

Regulatory AffairsPharmacovigilance OperationsQuality Assurance

Document identifiers

FDA-2026-D-0001

PV impact

Reinforces post-marketing safety reporting requirements for ANDA holders, ensuring consistent submission of safety data and periodic reports to the FDA.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 4, 2026

Full briefing

Practical implication

Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.

The guidance reinforces post-marketing safety reporting obligations for ANDA holders, including consistent submission of safety data and periodic reports to FDA.

What changed: FDA published final guidance on certain postapproval requirements for ANDA holders, reiterating obligations for post-approval supplements, annual reports, and post-marketing safety reporting under 21 CFR 314.80.

Why it matters: This guidance impacts all ANDA holders by clarifying FDA expectations for safety reporting and maintenance, ensuring compliance with post-marketing pharmacovigilance requirements.

Practical implication: Review the guidance to ensure compliance with post-marketing safety reporting timelines and annual report submissions; update SOPs for ICSR processing and periodic report generation.

View original source

Published from the Firecrawl policy change extraction pipeline.

#FDA#ANDA#Post-approval Requirements#Safety Reporting#Guideline#final#US Food and Drug Administration (FDA)#Reporting Requirement

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward